MedPath

Centro Nacional de Investigaciones Oncologicas CARLOS III

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:0
Completed:8

Trial Phases

3 Phases

Early Phase 1:2
Phase 1:3
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (37.5%)
Phase 2
3 (37.5%)
Early Phase 1
2 (25.0%)

High Definition Medicine for Solid Tumors Oncology

Recruiting
Conditions
Metastatic Solid Tumor
Advanced Cancer
First Posted Date
2024-09-11
Last Posted Date
2024-09-19
Lead Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Target Recruit Count
300
Registration Number
NCT06590506
Locations
🇪🇸

Hospital Universitario A Coruña, La Coruña, A Coruña/ Galicia, Spain

🇪🇸

Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain

🇪🇸

Hospital Son Espases, Palma De Mallorca, Mallorca / Baleares, Spain

and more 6 locations

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

Completed
Conditions
Prostate Cancer
First Posted Date
2017-03-09
Last Posted Date
2019-02-04
Lead Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Target Recruit Count
408
Registration Number
NCT03075735

SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Steroids switch
First Posted Date
2016-10-10
Last Posted Date
2017-01-27
Lead Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Target Recruit Count
26
Registration Number
NCT02928432
Locations
🇪🇸

Spanish National Cancer Research Centre (CNIO), Madrid, Spain

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

Conditions
Advanced Prostate Cancer
Radium 223
Castration Resistant
Interventions
Drug: Radium 223 55mBq/Kg every 4 weeks intravenously
First Posted Date
2016-10-06
Last Posted Date
2020-01-27
Lead Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Target Recruit Count
161
Registration Number
NCT02925702
Locations
🇪🇸

Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain

🇪🇸

Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

🇪🇸

Hospital Universitario de Elche, Elche, Alicante, Spain

and more 60 locations

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

Conditions
Castration Resistant
Advanced Prostate Cancer
Enzalutamide
First Posted Date
2016-10-04
Last Posted Date
2020-01-27
Lead Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Target Recruit Count
187
Registration Number
NCT02922218
Locations
🇪🇸

Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain

🇪🇸

Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

🇪🇸

ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain

and more 23 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.